[go: up one dir, main page]

MA34646B1 - Procedes de traitement du psoriasis en utilisant des antagonistes d'il-17 - Google Patents

Procedes de traitement du psoriasis en utilisant des antagonistes d'il-17

Info

Publication number
MA34646B1
MA34646B1 MA35872A MA35872A MA34646B1 MA 34646 B1 MA34646 B1 MA 34646B1 MA 35872 A MA35872 A MA 35872A MA 35872 A MA35872 A MA 35872A MA 34646 B1 MA34646 B1 MA 34646B1
Authority
MA
Morocco
Prior art keywords
antagonists
methods
treating psoriasis
antibody
binding molecule
Prior art date
Application number
MA35872A
Other languages
English (en)
Inventor
Achim Guettner
Matthias Machacek
Charis Papavassilis
Oliver Sander
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44759699&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA34646(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MA34646B1 publication Critical patent/MA34646B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne de nouveaux régimes pour le traitement du psoriasis, qui utilisent une quantité thérapeutiquement efficace d'un antagoniste de IL-17, tel qu'une molécule de liaison à IL-17, par exemple un anticorps de IL-17 (tel que l'anticorps secukinumab), ou une molécule de liaison à un récepteur de IL-17, par exemple un anticorps du récepteur de IL-17.
MA35872A 2010-10-08 2013-05-03 Procedes de traitement du psoriasis en utilisant des antagonistes d'il-17 MA34646B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39138810P 2010-10-08 2010-10-08
PCT/EP2011/067522 WO2012045848A1 (fr) 2010-10-08 2011-10-07 Méthodes de traitement du psoriasis au moyen d'antagonistes de il-17

Publications (1)

Publication Number Publication Date
MA34646B1 true MA34646B1 (fr) 2013-11-02

Family

ID=44759699

Family Applications (1)

Application Number Title Priority Date Filing Date
MA35872A MA34646B1 (fr) 2010-10-08 2013-05-03 Procedes de traitement du psoriasis en utilisant des antagonistes d'il-17

Country Status (28)

Country Link
US (9) US9717791B2 (fr)
EP (5) EP2625199B1 (fr)
JP (2) JP5537740B2 (fr)
KR (3) KR20130110179A (fr)
CN (2) CN107029234A (fr)
AU (1) AU2011311482B2 (fr)
BR (1) BR112013008501A2 (fr)
CA (1) CA2813900C (fr)
CL (1) CL2013000930A1 (fr)
CY (1) CY1119942T1 (fr)
DK (1) DK2625199T3 (fr)
ES (1) ES2660770T3 (fr)
HK (1) HK1247932A1 (fr)
HR (1) HRP20180301T1 (fr)
HU (1) HUE038334T2 (fr)
IL (1) IL225310A (fr)
LT (1) LT2625199T (fr)
MA (1) MA34646B1 (fr)
MX (1) MX356279B (fr)
NO (1) NO2625199T3 (fr)
PH (1) PH12013500660B1 (fr)
PL (1) PL2625199T3 (fr)
PT (1) PT2625199T (fr)
RU (2) RU2591083C2 (fr)
SG (1) SG188979A1 (fr)
SI (1) SI2625199T1 (fr)
TW (2) TWI548419B (fr)
WO (1) WO2012045848A1 (fr)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7767206B2 (en) 2006-10-02 2010-08-03 Amgen Inc. Neutralizing determinants of IL-17 Receptor A and antibodies that bind thereto
JO3244B1 (ar) 2009-10-26 2018-03-08 Amgen Inc بروتينات ربط مستضادات il – 23 البشرية
PL3295957T3 (pl) 2010-01-15 2020-03-31 Kirin-Amgen, Inc. Formulacja przeciwciała przeciwko IL-17RA i reżimy terapeutyczne do leczenia łuszczycy
EP3546483A1 (fr) 2010-05-20 2019-10-02 Ablynx N.V. Matériaux biologiques associés à her3
TWI618543B (zh) 2010-11-05 2018-03-21 諾華公司 Ｉｌ-１７抗體用於製備治療強直性脊椎炎之藥物之用途
UA117218C2 (uk) 2011-05-05 2018-07-10 Мерк Патент Гмбх Поліпептид, спрямований проти il-17a, il-17f та/або il17-a/f
EP2783014A1 (fr) * 2011-11-21 2014-10-01 Novartis AG Procédés de traitement du rhumatisme psoriasique (psa) utilisant des antagonistes d'il-17 et des allèles répondeurs ou non répondeurs à psa
AU2014238148A1 (en) * 2013-03-15 2015-10-08 Amgen Inc. Methods for treating psoriasis using an anti-IL-23 antibody
AP2015008801A0 (en) * 2013-03-15 2015-10-31 Amgen Inc Methods for treating crohn's disease using an anti-il23 antibody
EP4223312A1 (fr) * 2013-08-15 2023-08-09 Novartis AG Procédés de traitement du psoriasis en plaques à l'aide d'antagonistes de l'il-17
US11421025B2 (en) 2013-12-27 2022-08-23 Osaka University Treatment of IL-17A diseases
RU2577228C2 (ru) * 2014-03-14 2016-03-10 Закрытое Акционерное Общество "Биокад" Анти-il-17-антитела, способ их получения и способ применения
AU2015241373B2 (en) * 2014-03-31 2020-11-05 Amgen K-A, Inc. Methods of treating nail and scalp psoriasis
US11548940B2 (en) * 2014-05-15 2023-01-10 Rani Therapeutics, Llc Anti-interleukin antibody preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
AU2015258859B2 (en) 2014-05-15 2020-07-23 Rani Therapeutics, Llc Pharmaceutical compositions and methods for fabrication of solid masses comprising polypeptides and/or proteins
KR102427097B1 (ko) * 2014-08-26 2022-08-01 암젠 케이-에이, 인크. 항-tnf-알파 항체 요법을 받은 건선 환자의 치료 방법
LT3191120T (lt) * 2014-09-10 2024-07-25 Novartis Ag Il-17 antagonistų panaudojimas struktūrinio pažeidimo progresavimui slopinti, sergant psoriaziniu artritu
AR103172A1 (es) * 2014-12-22 2017-04-19 Novartis Ag Reducción selectiva de residuos de cisteina en anticuerpos il-17
AR103173A1 (es) 2014-12-22 2017-04-19 Novarits Ag Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17
CA2978449A1 (fr) 2015-03-02 2016-09-09 180 Therapeutics Lp Methode de traitement d'un trouble fibrotique localise a l'aide d'un antagoniste de l'il-33
EP3167892A1 (fr) 2015-11-10 2017-05-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Procédés et compositions pharmaceutiques pour la prévention ou le traitement de maladies intestinales inflammatoires
SG11201802887PA (en) * 2015-10-27 2018-05-30 Ucb Biopharma Sprl Methods of treatment using anti-il-17a/f antibodies
US20190194311A1 (en) 2016-07-19 2019-06-27 Novartis Ag Methods of treating new-onset plaque type psoriasis using il-17 antagonists
WO2018096467A1 (fr) * 2016-11-28 2018-05-31 Novartis Ag Méthodes de traitement de l'acné à l'aide d'antagonistes de l'interleukine-17 (il -17)
WO2018158741A1 (fr) * 2017-03-03 2018-09-07 Novartis Ag Modification de la maladie du psoriasis suite à un traitement à long terme avec un antagoniste de l'il-17
EP3672988A1 (fr) * 2017-08-23 2020-07-01 Eli Lilly and Company Traitement du psoriasis génital
TWI725532B (zh) * 2018-09-11 2021-04-21 美商美國禮來大藥廠 治療牛皮癬之方法
US20220267432A1 (en) 2019-07-30 2022-08-25 Jiangsu Hengrui Medicine Co., Ltd. Method for treating autoimmune disease by il-17 antagonist
TW202539734A (zh) 2019-09-20 2025-10-16 瑞士商諾華公司 使用白細胞介素-17（il-17）拮抗劑治療自體免疫性疾病之方法
CN116685605A (zh) * 2020-12-17 2023-09-01 上海华奥泰生物药业股份有限公司 靶向il-17a和il-36r的双特异性抗体及其应用
TW202246329A (zh) * 2021-03-03 2022-12-01 大陸商蘇州盛迪亞生物醫藥有限公司 抗il-17抗體治療自體免疫性疾病和炎症的方法
WO2023186174A1 (fr) * 2022-04-01 2023-10-05 Zai Lab (Shanghai) Co., Ltd. Formulation topique comprenant une molécule de liaison à l'il-17 et ses utilisations
CN116593718B (zh) * 2023-07-18 2023-09-15 军科正源（北京）药物研究有限责任公司 用于检测司库奇尤单抗抗药性抗体的试剂

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9422306D0 (en) * 1994-11-04 1994-12-21 Sandoz Ltd Organic compounds
US6093745A (en) * 1997-11-25 2000-07-25 Psorx, L.L.C. Methods and composition for treating skin proliferative diseases
AU2002224417A1 (en) * 2000-10-18 2002-04-29 Immunex Corporation Methods for treating il-18 mediated disorders
US20090280065A1 (en) * 2006-04-10 2009-11-12 Willian Mary K Uses and Compositions for Treatment of Psoriasis
TWI556829B (zh) * 2004-04-09 2016-11-11 艾伯維生物技術有限責任公司 用於治療ＴＮＦα相關失調症之多重可變劑量療法
GB0417487D0 (en) * 2004-08-05 2004-09-08 Novartis Ag Organic compound
PL1933869T3 (pl) * 2005-09-01 2010-06-30 Merck Sharp & Dohme Zastosowanie antagonistów IL-23 i IL-17 do leczenia autoimmunologicznej zapalnej choroby oczu
SI1963368T1 (sl) 2005-12-13 2012-11-30 Lilly Co Eli Anti il protitelesa
TW200815469A (en) * 2006-06-23 2008-04-01 Astrazeneca Ab Compounds
RU2367429C2 (ru) 2007-01-30 2009-09-20 Государственное учреждение Научно-исследовательский институт клинической иммунологии СО РАМН Способ лечения псориаза
EP2152318A4 (fr) * 2007-06-01 2011-12-07 Abbott Biotech Ltd Compositions et utilisations pour le traitement du psoriasis et de la maladie de crohn
RU2341272C1 (ru) 2007-10-22 2008-12-20 Левон Никитович Мкртчян Средство для неспецифической иммунотерапии
NZ591484A (en) * 2008-09-29 2012-09-28 Roche Glycart Ag Antibodies against human il 17 and uses thereof

Also Published As

Publication number Publication date
KR20150018595A (ko) 2015-02-23
SG188979A1 (en) 2013-05-31
US20200171147A1 (en) 2020-06-04
PH12013500660B1 (en) 2017-10-27
US20130202610A1 (en) 2013-08-08
DK2625199T3 (en) 2018-02-26
KR20140097566A (ko) 2014-08-06
US20250161444A1 (en) 2025-05-22
US20250161443A1 (en) 2025-05-22
EP3299390A1 (fr) 2018-03-28
TWI564022B (zh) 2017-01-01
US20230321231A1 (en) 2023-10-12
US11534490B2 (en) 2022-12-27
JP2014114288A (ja) 2014-06-26
BR112013008501A2 (pt) 2016-08-16
IL225310A (en) 2016-10-31
EP4137514A1 (fr) 2023-02-22
PH12013500660A1 (en) 2013-05-20
AU2011311482B2 (en) 2014-05-29
MX356279B (es) 2018-05-22
SI2625199T1 (en) 2018-03-30
JP2013543501A (ja) 2013-12-05
LT2625199T (lt) 2018-03-12
HUE038334T2 (hu) 2018-10-29
EP2625199A1 (fr) 2013-08-14
HK1247932A1 (en) 2018-10-05
HRP20180301T1 (hr) 2018-03-23
US9717791B2 (en) 2017-08-01
JP5537740B2 (ja) 2014-07-02
TW201630625A (zh) 2016-09-01
CA2813900C (fr) 2017-01-10
AU2011311482A1 (en) 2013-04-04
PT2625199T (pt) 2018-02-28
ES2660770T3 (es) 2018-03-26
TWI548419B (zh) 2016-09-11
NO2625199T3 (fr) 2018-04-21
US20170304439A1 (en) 2017-10-26
MX2013003916A (es) 2013-06-03
TW201216984A (en) 2012-05-01
RU2013120957A (ru) 2014-11-20
US10583190B2 (en) 2020-03-10
EP2625199B1 (fr) 2017-11-22
RU2665954C1 (ru) 2018-09-05
KR20130110179A (ko) 2013-10-08
RU2591083C2 (ru) 2016-07-10
CN107029234A (zh) 2017-08-11
CN103154031A (zh) 2013-06-12
EP4670788A2 (fr) 2025-12-31
CA2813900A1 (fr) 2012-04-12
EP3792281A1 (fr) 2021-03-17
IL225310A0 (en) 2013-06-27
CY1119942T1 (el) 2018-12-12
PL2625199T3 (pl) 2018-04-30
WO2012045848A1 (fr) 2012-04-12
US20250161445A1 (en) 2025-05-22
US20210113688A1 (en) 2021-04-22
KR101620771B1 (ko) 2016-05-12
CL2013000930A1 (es) 2014-03-28
US20210162044A1 (en) 2021-06-03

Similar Documents

Publication Publication Date Title
MA34646B1 (fr) Procedes de traitement du psoriasis en utilisant des antagonistes d'il-17
MA34647B1 (fr) Procedes de traitement de la polyarthriterhumatoide en utilisant des antagonistes dil-17
MA34175B1 (fr) Anticorps anti-cxcr4 humanisés pour le traitement de cancer
EA200900828A1 (ru) Соединения и композиции в качестве ингибиторов активности каннабиноидного рецептора 1
MA32655B1 (fr) Composés modulant sélectivement le récepteur cb2
MA44312A (fr) Anticorps et leurs méthodes d'utilisation
MA37946A1 (fr) Traitement de la polyarthrite rhumatoïde
DE602005020655D1 (de) Carboxamid-spirolactam-cgrp-rezeptor-antagonisten
MA32928B1 (fr) Anticorps anti-cxcr4 et leur utilisation pour le traitement du cancer
EA201290515A1 (ru) Аминопиримидины в качестве syk ингибиторов
EA200970337A1 (ru) Ингибиторы котранспортера натрий-глюкозы 2 и способы их применения
MA40662B1 (fr) Anticorps contre tigit
MA29330B1 (fr) Antagonistes de recepteur de pgd2 pour le traitement des maladies inflammatoires.
NO20092470L (no) Substituerte diazepanforbindelser som orexinreseptorantagonister
EP1608627A4 (fr) Antagonistes des recepteurs du cgrp spirohydantoine anilides bicycliques
EP1861399A4 (fr) Antagonistes du recepteur du cgrp
EP1606286A4 (fr) Antagonistes benodiazepine spirohydantoin des recepteurs de cgrp
MA30358B1 (fr) Quinazolines pour l'inhibition de pdk1
MA35404B1 (fr) Composés pour le traitement de la toxicomanie
ATE556060T1 (de) Monocyclische anilidspirohydantoine als cgrp- rezeptorantagonisten
MA38161A1 (fr) Anticorps anti-bmp-6
DE602005020656D1 (de) Bicyclische anilidspirolactame als antagonisten des cgrp-rezeptors
ATE517106T1 (de) Kondensierte spiropiperidine als modulatoren muskarinartiger rezeptoren
MA47221A1 (fr) Anticorps monoclonal à pd-l1
FR2942798B1 (fr) Peptides utilisables pour le traitement de la leucemie lymphoide chronique